Please login to the form below

Not currently logged in
Email:
Password:

belimumab

This page shows the latest belimumab news and features for those working in and with pharma, biotech and healthcare.

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

SRI4 measurements are tried and tested from a regulatory perspective, having been used to back the US approval of GlaxoSmithKline’s  Benlysta(belimumab) in 2011.

Latest news

More from news
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Building a business that is lean and specialised Building a business that is lean and specialised

    The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics